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ABSTRACT
Cortisol resistance (CR) is a rare disease characterized by a gener-
alized reduced sensitivity of end-organs to the actions of glucocorticoids
(GCs). GC effects are mediated by the GC receptor (GR). The molecular
alterations in CR described thus far were located in the hormone-binding
domain of the GR gene. Recent reports of a considerable prevalence of
abnormalities in the GR in patients attending the endocrine clinic
prompted us to carry out further investigations with respect to GR
protein and GR gene in patients attending the endocrine clinic for a
broad spectrum of complaints and biochemical evidence suggesting a CR.
In the present study, we describe five patients with biochemical
and clinical CR. All patients showed a diurnal rhythm of serum
cortisol concentrations (albeit at a high level), an insufficient sup-
pression of serum cortisol concentration in reaction to 1 mg dexa-
methasone (DEX), and variable degrees of androgen overproduction,
in the absence of clinical signs and symptoms of Cushing’s syndrome.
Three of the four female patients presented with complaints of an-
drogen overproduction, two of them in combination with fatigue. The
other female patient had severe steroid-resistant asthma. The only
male patient and his son were asymptomatic.
In four patients, we investigated receptor protein characteristics
on mononuclear leukocytes in a whole cell DEX binding assay and
studied the ability of DEX to inhibit mitogen-induced cell prolifera-
tion in mononuclear leukocytes in vitro. In all patients investigated,
we found alterations in receptor number or ligand affinity and/or the
ability of DEX to inhibit mitogen-induced cell proliferation.
To investigate the molecular defects leading to the clinical and
biochemical pictures in these patients, we screened the GR gene using
PCR/single-strand conformational polymorphism/sequence analysis.
No GR gene alterations were found in these patients.
In conclusion, the five patients described had clinical and biochem-
ical evidence of CR, but no abnormalities were demonstrated in the
GR gene.
Probably, as yet undefined alterations somewhere in the cascade
of events starting with ligand binding to the GR protein, and finally
resulting in the regulation of the expression of GC responsive genes,
or postreceptor defects or interactions with other nuclear factors form
the pathophysiologic basis of CR in these patients. (J Clin Endocrinol
Metab 85: 2076–2081, 2000)
CORTISOL RESISTANCE (CR) is a rare condition char-acterized by a generalized reduced sensitivity of end-
organs to glucocorticoids (GCs). The disease is typified by
increased serum cortisol levels, a normal circadian rhythm of
cortisol concentrations (albeit at an elevated level), relative
resistance of adrenal cortisol suppression to dexamethasone
(DEX), and the absence of the clinical stigmata of Cushing’s
syndrome (1). After the original description of a father and
son with CR by Vingerhoeds et al. (2), about 30 symptomatic
patients and asymptomatic family members have been iden-
tified (1–13). In generalized CR, the decreased sensitivity to
cortisol results in activation of the hypothalamo-pituitary-
adrenal (HPA) axis with increased ACTH and cortisol se-
cretion. In most cases, the elevated cortisol levels sufficiently
compensate to overcome peripheral CR. The elevated corti-
sol concentrations are beneficial in these patients, and no
signs or symptoms of Cushing’s syndrome are present. The
clinical presentation of CR is, in most instances, related to the
secondary ACTH-driven overproduction of adrenal andro-
gens and mineralocorticoids. Hypertension and hypokale-
mic acidosis may develop secondary to overproduction of
mineralocorticoids (1, 2). In females, the secondary overpro-
duction of adrenal androgens may result in acne, hirsutism,
menstrual irregularity, and infertility (1, 6). The overpro-
duction of adrenal androgens gives rise to signs of hyperan-
drogenism in females only because of the much higher go-
nadal androgen production in males compared with females.
In some patients with CR, chronic fatigue is the only symp-
tom (5), probably due to an insufficient overproduction of
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cortisol. Finally, several patients with steroid-resistant
asthma have been described, which in two cases seemed to
be caused by generalized CR (13).
The biological effects of cortisol are mediated by the GC
receptor (GR), a member of the family of intracellular hor-
mone receptors (14), to which the vitamin D and retinoic acid
receptors belong as well. These receptors are characterized
by a three-domain structure: a carboxy-terminal ligand-bind-
ing domain, a central DNA-binding domain, and an N-ter-
minal domain responsible for the interactions with other
transcription factors (14). Hormone-bound GRs translocate
to the nucleus and regulate the expression of GC-responsive
genes.
It has become clear from previous studies that the molec-
ular basis of CR may be located in the GR gene. Up to the
present, this has been elucidated in six different kindreds
(15–20), in which mutations in the hormone-binding domain
of the GR gene seemed to be the cause of CR.
Because of the large variation in clinical manifestation of
CR, the disease might be less rare than previously thought.
In six patients described previously, at least three different
clinical forms of CR could be identified (1).
In the present study, we report five additional patients
with very diverse clinical presentations. Eventually, in all
patients clinical and/or biochemical CR was diagnosed.
Using PCR/single-strand conformational polymorphism
(SSCP) and sequence analysis, we screened the GR gene in
these patients for alterations, to characterize the CR on the
molecular level as well. No evidence for mutations in the GR
gene was found in any of the patients, however. Suggestions
for other possible mechanisms of CR in these individuals are
made.
Materials and Methods
Biochemical determinations
The diagnostic procedures used in measuring the activity and re-
sponsiveness of the HPA axis in the patients tested in our own clinic have
been described previously (21, 22) Circulating and urinary cortisol,
ACTH, desoxycortisol, androstenedione, dehydroepiandrosterone, de-
hydroepiandrosterone sulfate, and testosterone levels were determined
by RIA kits. The inter- and intra-assay variations of these determinations
have been reported previously (1).
Peripheral blood mononuclear cells
Blood (40 mL) was drawn into heparinized tubes between 0800 h and
0900 h by vena puncture. Peripheral blood mononuclear leukocytes
(PBMLs) were isolated as described previously (23). The blood was
diluted 2-fold with saline and layered over Ficoll-Hypaque (Pharmacia,
Uppsala, Sweden). The PBML-enriched interphase was isolated and
washed twice with saline. The final cell pellet was resuspended in 15 mL
RPMI-1640 medium (Gibco Europe, Breda, The Netherlands), contain-
ing 15 mm HEPES, 10% charcoal-absorbed FCS (Amstelstad/Flow,
Zwanenburg, The Netherlands), 2 mm glutamine, 100 U/mL penicillin,
100 mg/mL streptomycin, and 1.5 mg/mL fungizone. The cells were
incubated for 30 min at 37 C in a shaking water bath to remove endog-
enous cortisol. The cell suspension was centrifuged and resuspended in
15 mL medium. This procedure was repeated twice more. Finally, the
cells were resuspended at a density of 2.5–10 3 106 cells per mL in the
medium.
Whole cell DEX-binding assay
The whole cell DEX-binding assay was performed as described pre-
viously (23). Briefly, incubation was started in a volume of 240 mL
(0.5–2 3 106 cells) containing 3H-DEX at concentrations of 1.3–40 nm
without (total binding) and with (nonspecific binding) a 400-fold excess
of unlabeled DEX. Two tubes without labeled DEX were incubated
under the same conditions for determination of cell number and viability
at the end of the procedure. The tubes were incubated during 1 h at 30
C in a shaking water bath. The incubation was stopped by the addition
of 2 mL cold saline, followed by centrifugation and two washing steps.
Finally, the cells were resuspended in 250 ml medium. Radioactivity in
200 ml of this suspension was counted in a liquid scintillation counter.
Specific binding was calculated by subtracting nonspecific binding from
total binding. Receptor number and ligand affinity (1/Kd) were calcu-
lated from the data using the method of Scatchard (24). Normal values
for the number of receptors per cell (6352 6 310 per cell) and Kd (7.7 6
0.4 nmol/L) were described previously (1, 25)
Inhibition of mitogen-stimulated incorporation of [3H]-
thymidine by DEX
The sensitivity of mononuclear leukocytes to the inhibition of phy-
tohaemagglutinin-stimulated incorporation of [3H]-thymidine by DEX
was determined, as described previously (1). After isolation, mononu-
clear leukocytes were seeded, and phytohaemagglutinin (5 mg/mL) and
DEX in nine concentrations between 0 and 1000 nmol/L were added.
The cells were incubated at 37 C during 96 h. The last 4 hours of
incubation was in the presence of 0.5 mCi of [3H]-thymidine. At the end
of the incubation, the cells were harvested and washed, and incorpo-
rated [3H]-thymidine was measured by liquid scintillation counting. The
concentration of DEX necessary to achieve 50% of the maximal inhibition
(IC50) was calculated. Normal values for IC50 (,15 nmol/L) were de-
scribed previously (1, 25)
PCR/SSCP analysis of the GR gene
DNA was isolated from peripheral blood leukocytes using standard
techniques. PCR amplification of the GR gene was carried out using
primer sequences and amplification conditions previously described by
Karl et al. (16). SSCP analysis of the PCR products was carried out using
0.5 3 MDE polyacrylamide gels (J.T. Baker Chemicals, Deventer, The
Netherlands) at 4 C in the presence and absence of 5% glycerol, generally
as described by Orita et al. (26). DNA fragments displaying an abnormal
migration pattern during SSCP analysis were subject to direct sequenc-
ing using a modified Sanger-dideoxynucleotide chain termination
method (16, 27). In all patients, a second PCR amplification of the exons
2 and 4–9 of the GR gene was carried out using other primer sequences
(data not shown; sequences available on request), to obtain PCR frag-
ments with a length of about 200 nucleotides. SSCP analysis of the PCR
fragments was carried out as described above. Finally, PCR fragments
of exons 4–9 (coding for the hormone-binding domain of the GR) in all
patients and of the whole coding part of the GR gene in patients 1 and
2 were subjected to direct sequencing as described by Karl et al. (16).
Results
Patient 1
Patient 1 was first investigated at the age of 18 yr because
of hirsutism and menstrual irregularities. Physical examina-
tion revealed profound hirsutism on the arms, legs, chest,
and face. She had a round face and acne and generalized
obesity.
Endocrine testing showed an intact diurnal rhythm of
plasma cortisol concentrations at an elevated level. 24-h uri-
nary cortisol secretion was twice the upper limit of normal.
Serum ACTH levels were in the higher normal range. A 1-mg
overnight DEX suppression test (DST) showed insufficient
cortisol suppression (323 nmol/L; N, ,140 nmol/L). Addi-
tional studies showed increased androstenedione (24.4
nmol/L) and testosterone (3.4 nmol/L) levels. At that time,
the diagnosis of pituitary-dependent Cushing’s syndrome
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was made and a left-sided adrenalectomy was performed,
followed by external pituitary radiation.
Twelve years after the first admission, the patient was
screened with respect to cortisol receptor characteristics. It
seemed that she had a normal number of receptors per cell
in mononuclear leukocytes, and also the ligand-binding af-
finity of the receptors was normal (n, 7429 receptors/cell; Kd,
8.6 nmol/L). From the mitogen-induced proliferation assay,
however, it became clear that the PBMLs were insensitive to
DEX (Fig. 1). PCR/SSCP analysis of the GR gene showed an
abnormal pattern in the N-terminal part of exon 2. Sequence
analysis of the fragment revealed the presence of a poly-
morphism, leading to a GAG to GAA (both Glu) in codon 22
and an AGG to AAG (Arg to Lys) change in codon 23, as
described previously by Koper et al. (27). Further sequence
analysis of the whole coding part of the GR gene revealed no
additional alterations.
Based on clinical and biochemical findings, the diagnosis
of generalized CR was made and a treatment with low doses
of DEX (1 mg) at night was started. Cortisol, androstenedi-
one, and testosterone levels normalized during DEX treat-
ment, and there was a slight improvement of the hirsutism.
Patient 2
Patient 2, a girl born in 1976, presented at the age of 7 yr
with very severe asthma. When she was referred to our clinic
at the age of 17 yr she had been treated with 25 mg pred-
nisone daily continuously for 2 yr, which regularly had to be
elevated to a dose of 60 mg per day over a period of 10–12
days. Despite this therapeutic regimen, she still had severe
complaints of asthma, not allowing her to live a normal life.
Because of this very poor clinical response to therapy in the
absence of the development of signs or symptoms of exog-
enous Cushing’s syndrome, she was referred to our clinic for
further investigation with respect to the GR gene.
Physical examination revealed a tall, slender young
woman without signs or symptoms of Cushing’s syndrome.
Despite continuous high-dose prednisone therapy during
puberty, her final height was over 10 cm above the parents’
height (1.70 m). Because of the high dose of prednisone the
patient was taking, we were not able to perform regular
testing of the HPA axis. Furthermore, as became clear from
a previous study (23), prednisone is an agent that interferes
with the whole cell DEX-binding assay and the mitogen-
induced thymidine incorporation assay, making it impossi-
ble to obtain meaningful results from these tests.
Using PCR/SSCP analysis, we found the same polymor-
phism as described for patient 1 in exon 2 of the GR gene. No
other mutations were found despite sequencing of the whole
coding part of the GR gene.
The patient’s family was tested with respect to CR as well.
They were all healthy without clinical signs of GR. All family
members showed a normal cortisol suppression in the 1-mg
overnight DST. Nevertheless, it seemed that the grand-
mother, the mother, and the oldest brother showed the same
polymorphism in exon 2 of the GR gene.
Patient 3
Patient 3 is a 65-yr-old man. Hypertension was diagnosed
at the age of 50. Fifteen years before presentation, a computed
tomography (CT) scan revealed a tumor in the right kidney
and a tumorous-enlarged right adrenal gland. He underwent
a partial right-sided nefrectomy in combination with an ad-
renalectomy. Histopathological evaluation revealed an infil-
trating clear-cell adenocarcinoma of the kidney and nodular
adrenal hyperplasia.
Two years later, he presented with obesity and insulin
resistance. Early morning cortisol concentration was 432
nmol/L (normal), whereas 24-h urinary cortisol excretion
was increased to 2-fold over the normal range. Five years
later, a CT scan revealed a nodule of 2 cm in a nodular-
enlarged left adrenal gland. There were no clinical symptoms
of Cushing’s syndrome.
Endocrine testing at that time showed normal serum cor-
tisol levels with a normal diurnal rhythm and high normal
ACTH concentrations. There was an insufficient suppression
of cortisol in the overnight 1-mg DST (471 nmol/L). In re-
sponse to the iv administration of 0.1 U/kg insulin, he de-
veloped hypoglycemia, followed by a just subnormal in-
crease in cortisol levels (from 546 to maximally 687 nmol/L).
Three years later, a CT scan confirmed nodular hyperpla-
sia of the left adrenal gland. A CT scan of the pituitary
revealed no abnormalities. At present, he is still asymptom-
atic without signs or symptoms of Cushing’s syndrome.
In the whole cell DEX-binding assay, a normal number of
GRs per cell in PBMLs were seen (6659 receptors/cell),
whereas a diminished affinity for DEX existed with a Kd of
22.3 nmol/L (Fig. 2). In the mitogen-induced proliferation
assay, a maximal inhibition of 77% could be achieved with
an IC50 of 33.1 nmol/L, which is in the high normal range.
Using PCR/SSCP analysis of the whole coding part of the
GR gene in combination with sequence analysis of the whole
hormone-binding domain (exons 4–9), no alterations in the
GR gene could be identified.
The patient’s three sons and daughter were tested with
respect to CR as well. One of the sons had an increased 24-h
FIG. 1. Mitogen-induced proliferation assay in patient 1 (circles), pa-
tient 4 (triangles), and a healthy control (squares). In both patients
DEX showed an absent capacity to inhibit mitogen-induced cell pro-
liferation.
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urinary cortisol excretion. He was a healthy young man with
normal blood pressure. In the 1-mg overnight DST, an in-
sufficient cortisol suppression occurred to 364 nmol/L. Also
in the son, no alterations in the GR gene were identified.
Patient 4
Patient 4 is a 33-yr-old schoolteacher who, over the past
few years, developed irregular menstruations, acne, increas-
ing hair growth on the face, increasing fatigue, and an un-
stable mood. Biochemical examination in another hospital
pointed toward the existence of pituitary-dependent Cush-
ing’s syndrome. She underwent transsphenoidal pituitary
surgery, during which normal pituitary tissue was removed.
Because the complaints persisted, she was referred to our
clinic.
Physical examination revealed a young woman without
clinical stigmata of Cushing’s disease. There was a slight
increase in facial hair growth.
Endocrine testing revealed elevated early morning cortisol
levels (1355 nmol/L) and a slightly disturbed circadian
rhythm. 24-h urinary cortisol excretion was twice the upper
limit of normal. The overnight DST revealed an insufficient
cortisol suppression (857 nmol/L). ACTH concentrations
were within the normal range. In response to the iv admin-
istration of 0.1 U/kg insulin, she developed hypoglycemia,
followed by a normal increase in the basally elevated cortisol
levels (from 920-1177 nmol/L), as well as of GH levels (from
3.0–19.7 mg/L). Additional studies showed normal serum
androgen concentrations. Bone mineral density measure-
ments showed a completely normal age- and sex-standard-
ized level.
A whole cell DEX-binding assay, showed a normal num-
ber of binding sites per cell on PBMLs (5938 receptors/cell),
but the ligand affinity of the receptors was significantly low-
ered (Kd 17.4 nmol/L, Fig. 2). Also, in the mitogen-induced
proliferation assay an insensitivity to DEX became apparent
(Fig. 1).
PCR/SSCP analysis of the whole coding part of the GR
gene showed no abnormal migration patterns. Furthermore,
sequence analysis of the hormone-binding domain of the GR
gene (exons 4–9) revealed no alterations in this part of the
gene.
Her parents and only sister were healthy and showed a
normal cortisol suppression in an overnight 1-mg DST.
Based on the clinical and biochemical data, the diagnosis
of generalized CR was made. The patient has been treated
with low doses of DEX (0.5 mg overnight) for the past 12
months. Within a couple of weeks, a dramatic improvement
of the clinical course was observed: fatigue and mental in-
stability greatly improved. The patient started working again
and jogs 10 km every other day. Cortisol concentrations
remained elevated (829 nmol/L), and adrenal androgen pro-
duction was slightly suppressed. Probably, this low dose of
DEX was a sufficient dose to induce the clinical improvement
in the patient, but was not high enough to completely sup-
press the HPA axis.
Patient 5
Patient 5 is a 33-yr-old woman who was admitted for
analysis of severe tiredness, hirsutism, and oligomenorrhea.
Furthermore, there were complaints of muscle weakness. She
was no longer able to perform her job as a schoolteacher.
Endocrine testing showed a normal circadian rhythm of
cortisol at a normal level, normal ACTH levels, and a normal
urinary cortisol excretion. There was an insufficient cortisol
suppression in reaction to the administration of 1 mg DEX
(503 nmol/L). A normal GH response in reaction to an in-
sulin-induced hypoglycemia was observed (from 0.3–27.3
mg/L), but cortisol concentrations did not increase suffi-
ciently (from 402–481 nmol/L). Serum androstenedione lev-
els were increased (27.2 nmol/L). The patient had no broth-
ers or sisters, and her parents were both healthy and showed
normal cortisol concentrations and a normal adrenal cortisol
suppression in an overnight 1-mg DST.
Analysis of cortisol receptor characteristics in mononu-
FIG. 3. Whole cell DEX-binding assay in patient 5 (squares) and a
healthy control (circles). The patient showed only half of the normal
receptor number per cell.
FIG. 2. Whole cell DEX-binding assay in patients 3 (triangles) and 4
(squares) and a healthy control (circles). Both patients showed a
decreased affinity of the GR to DEX.
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clear leukocytes showed a normal Kd (8.1 nmol/L) in com-
bination with a significantly lowered number of receptors
per cell (3500 receptors/cell; Fig. 3). The bioassay showed a
normal capacity to inhibit mitogen-induced proliferation
(IC50, 27.7 nmol/L). PCR/SSCP analysis of the whole coding
part of the GR gene showed no abnormal migration patterns.
Furthermore, sequence analysis of the hormone-binding do-
main of the GR gene (exons 4–9) revealed no alterations in
this part of the gene.
Based on the clinical and biochemical finding, the diag-
nosis of partial CR was made. The patient has been treated
with low doses of DEX (0.5 mg overnight) for the past 12
months. Androstenedione levels slightly decreased (to 17.6
nmol/L). Hirsutism has improved, and the menstrual pat-
tern normalized. Furthermore, tiredness improved dramat-
ically, and the patient feels well for the first time in years and
started to work again on a regular basis.
Discussion
Ever since the first description 1976 by Vingerhoeds et al.
(2), only about 30 patients and (asymptomatic) family mem-
bers with CR have been described. Up until now, the mo-
lecular basis for CR has been described in six patients and
affected (asymptomatic) family members (15–20). In all six
cases, mutations in the hormone-binding domain of the GR
gene were responsible for the clinical manifestation of CR.
Recent reports of a considerable prevalence of possible ab-
normalities in the GR in patients attending the endocrine
clinic for hypokalemia, hypertension, acne, hirsutism, and
menstrual disorders (1, 11) prompted us to carry out a thor-
ough investigation with respect to the GR protein and the GR
gene in patients attending the endocrine clinic for a broad
spectrum of complaints suggesting a possible CR. In the
present study, we describe five patients with variable clinical
presentation that all seem attributable to generalized CR.
All patients demonstrated an intact or nearly intact diurnal
rhythm of serum cortisol concentrations, an insufficient sup-
pression of serum cortisol concentrations in reaction to 1 mg
DEX, variable degrees of androgen overproduction, and the
absence of clinical signs and symptoms related to long-term
exposure of the body to increased cortisol production.
In patients 4 and 5, fatigue was (besides signs of hyperan-
drogenism) an additional complaint. In a previous report by
Bronnegard et al. (5), a family with CR was described, in
whom chronic fatigue was the only symptom. It was hy-
pothesized that there was an insufficient compensation by
increased GC secretion in certain target tissues, like, for ex-
ample, the central nervous system. In patient 5, treatment
with low doses of DEX improved the feelings of tiredness. In
this patient, an insufficient increment of GC secretion to
overcome the CR might be the explanation for the clinical
picture.
Patient 2 was a young girl with severe steroid-resistant
asthma. She had not developed adverse effects with respect
to signs and symptoms of Cushing’s syndrome. It was strik-
ing that there was no growth impairment during puberty,
and her final length was well above her parents’ length.
Because of the GC therapy, we could not perform endocri-
nological testing nor determine receptor protein character-
istics. Nevertheless, the CR diagnosis was based on the com-
plete absence of signs and symptoms of Cushing’s syndrome.
The results of a number of studies (28–30) suggest that in
cases of rheumatoid arthritis, asthma, and sepsis, high local
concentrations of cytokines induce a localized CR at the site
of inflammation, which can insufficiently be overcome by
excess exogenous GCs. This reversible cytokine-induced
form of CR should be differentiated from the situation in our
patient in whom steroid-resistant asthma was probably due
to an irreversible (generalized), which was previously de-
scribed in two patients by Sher et al. (13). This differentiation
can be made on the bases of the appearance of side effects:
in patients with cytokine-induced CR, GCs do have delete-
rious systemic effects, whereas in patients with generalized
CR no side effects of treatment with high doses of GCs are
seen.
To search for possible alterations in the GR gene explain-
ing the clinical pictures in the patients described in this study,
PCR/SSCP analysis of the whole coding part of the GR gene
was performed. Furthermore, the hormone-binding domain
of the GR gene (exons 4–9) was screened using sequence
analysis. Two of the patients described carried a polymor-
phism characterized by a double point mutation at codons 22
and 23. This polymorphism has previously been described in
a general population screening by Koper et al. (27). In that
study, a 1-mg overnight DST was performed in 216 healthy
elderly individuals. The same polymorphism was found in
this population study in eleven individuals, including the
person with the highest post-DEX cortisol concentration (256
nmol/L). Moreover, two other subjects with diminished cor-
tisol suppression (post-DEX cortisol concentrations were 110
and 241 nmol/L, respectively) were found to carry the same
mutation. However, eight other subjects out of this group of
216 volunteers, showed this polymorphism in combination
with a normal cortisol suppression in reaction to 1 mg DEX.
From patient 2, we screened her family with respect to this
polymorphism as well. It seemed that her healthy grand-
mother, mother, and brother carried the mutation. They all
showed a normal cortisol suppression in the 1-mg DST. In in
vitro expression experiments, this polymorphism showed no
alterations in the efficacy of the GR to activate transcription
in such systems compared to the wild-type receptor (31).
Possibly, in the patients with CR carrying this polymor-
phism, the mutation is linked to another mutation/polymor-
phism in or near the GR gene that was not detected in our
study using the PCR/SSCP/sequence approach.
In patients 3–5, who all showed clear clinical and bio-
chemical pictures of CR, no GR gene alterations were found,
however. It is clear that there is a discrepancy between the
clinical and biochemical picture in these patients, on the one
side, and the molecular characterization, on the other side.
This is especially true for the patients who showed a lowered
Kd. In these patients one would expect to find alterations in
the hormone-binding domain of the GR gene. Patient 5
showed only half of the normal numbers of GR per cell in
PBMLs. In a family with only half of the number of receptors
previously described by Karl et al. (16), it seemed that this
was due to a splice site mutation in one of the alleles of the
GR gene, resulting in an unstable messenger RNA. Another
possibility might be that there is a mutation/deletion in one
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of the alleles that alters the structure of the hormone-binding
domain in such a way that no ligand can be bound. On the
other hand, one would expect to find such alterations using
PCR/SSCP/sequence analysis.
Not only GR expression level and ligand-binding affin-
ity, but also ligand-induced GR conformation changes,
dissociation from heat shock proteins, phosphorylation,
and nuclear transformation are important determinants of
GC sensitivity (32). Another possibility could be that pos-
treceptor defects or interactions with other nuclear cofac-
tors form the pathophysiologic basis of CR in these pa-
tients. To investigate the GR gene more extensively, a next
step will be to look at the transcriptional level by studying
messenger RNA expression.
It can be concluded that in all five patients described, there
was clinical and/or biochemical evidence for generalized
CR. On the other hand, we could not identify GR gene al-
terations that give a molecular explanation for the clinical
and biochemical CR.
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